Available Technological Offer
Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the treatment of immune diseases cursed with Th1/Th2 imbalance or as vaccine adjuvants.
Inhibitor of Interferon type I (IFN-I) is capable of inhibiting the inflammatory response in those autoimmune diseases in which this cytokine is involved, called interferonopathies, such as systemic lupus erythematosus and Aicardi-Goutières syndrome.
A new immunotherapy strategy based on the administration of ADCs or CAR-T cells derived from a monoclonal antibody specific for the pre-TCR receptor, which impairs LIC activity and tumor progression, has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.
New tiourea- and urea-based glycolipids with immunomodulatory activity. The compounds are Mincle agonist and have shown in vitro and in vivo immunostimulant activity. They can be used as vacine adjuvants, in the modulation of the immune response and in the treatment of infectious disease or cancer.